| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Revenue | $0 | -100.0% |
| Cost of Revenue | $0 | -100.0% |
| Gross Profit | $0 | -100.0% |
| R&D Expense | $99.5M | +55.8% |
| SG&A Expense | $40.3M | +33.3% |
| Operating Income | -$1.79B | -888.2% |
| Pre-tax Income | -$1.68B | -857.5% |
| Income Tax | -$4.3M | +59.3% |
| Net Income | -$578.6M |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $199.4M | -39.4% |
| Current Assets | $343.8M | -33.0% |
| Total Assets | $599.7M | -73.9% |
| Current Liabilities | $47.5M | +165.1% |
| Total Liabilities | $64.5M | -51.1% |
| Stockholders' Equity | $203.9M | -68.9% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$120.8M | -281.6% |
| Capital Expenditures | $33.2M | -51.6% |
| Investing Cash Flow | -$8.8M | +94.8% |
| Financing Cash Flow | -$230K | +95.3% |
| Free Cash Flow | -$154.0M | -53.5% |
| -1076.3% |
| EPS (Basic) | -$7.34 | -995.5% |
| EPS (Diluted) | -$7.34 | -995.5% |